Trial Profile
A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Hib-DTaP-poliovirus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational; Therapeutic Use
Most Recent Events
- 14 Aug 2012 Actual patient number changed from 600 to 613 as reported by ClinicalTrials.gov (Parent trial: NCT00366678).
- 14 Aug 2012 Actual patient number changed from 600 to 613 as reported by ClinicalTrials.gov (Parent trial: NCT00366678).
- 27 Apr 2012 Actual initiation adet changed from Apr 2010 to Feb 2010 as reported by European Clinical Trials Database (Extension trial: EudraCT2009-015321-37).